On 27 October 2023, Coherus BioSciences and Shanghai Junshi Biosciences received FDA approval for Loqtorzi (toripalimab), marking a significant milestone as the first-ever sanctioned treatment for nasopharyngeal carcinoma. The medication has gained approval for use alongside cisplatin and gemcitabine as an initial treatment for individuals diagnosed with metastatic or locally advanced nasopharyngeal carcinoma. The introduction of Loqtorzi is poised to become the new benchmark in patient care when employed in conjunction with chemotherapy.
With this recent approval, Junshi has triumphed over BeiGene as the first to obtain FDA approval for a China-produced PD-1 drug....